AN2 Therapeutics Insider Gilbert Lynn Marks Files Ownership Change

TL;DR

**Insider Gilbert Lynn Marks filed a Form 4 for AN2 Therapeutics, indicating a change in ownership.**

AI Summary

This Form 4 filing, dated March 23, 2026, indicates that Gilbert Lynn Marks, a reporting person, has filed a statement of changes in beneficial ownership of securities for AN2 Therapeutics, Inc. (CIK: 0001880438). While the filing itself doesn't detail specific transactions, it signals that Marks, who is associated with AN2 Therapeutics, has had a change in their ownership stake. This matters to investors because changes in insider ownership can sometimes signal confidence (or lack thereof) in the company's future prospects, potentially influencing stock price.

Why It Matters

Insider ownership changes can signal confidence or concern about a company's future, which can influence investor sentiment and stock performance.

Risk Assessment

Risk Level: low — This filing is purely administrative and does not inherently pose a direct risk, though the underlying transaction could be positive or negative.

Analyst Insight

A smart investor would look for the specific transaction details within the full Form 4 document to understand if Gilbert Lynn Marks bought or sold shares, and the quantity, to gauge insider sentiment towards AN2 Therapeutics, Inc.

Key Players & Entities

• Gilbert Lynn Marks (person) — Reporting Person
• AN2 Therapeutics, Inc. (company) — Issuer
• 0001916940 (person) — CIK for Gilbert Lynn Marks
• 0001880438 (company) — CIK for AN2 Therapeutics, Inc.

FAQ

Key Financial Figures

• $3.91 — 1. The exercise price of the option is $3.91 per share, representing the closing pri

Filing Documents

• ownership.html (4)
• ownership.xml (4) — 14KB
• 0001193125-26-120230.txt ( ) — 16KB

From the Filing

SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * Marks Gilbert Lynn (Last) (First) (Middle) C/O AN2 THERAPEUTICS, INC. 1300 EL CAMINO REAL, SUITE 100 (Street) MENLO PARK CALIFORNIA 94025 (City) (State) (Zip) UNITED STATES (Country) 2. Issuer Name and Ticker or Trading Symbol AN2 Therapeutics, Inc. [ ANTX ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) 2a. Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 03/19/2026 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (right to buy) $ 3.91 (1) 03/19/2026 A 10,665 (2) 04/29/2031 Common Stock 10,665 (3) 10,665 D Stock Option (right to buy) $ 6.596 03/19/2026 D 10,665 (2) 04/29/2031 Common Stock 10,665 (3) 0 D Stock Option (right to buy) $ 3.91 (1) 03/19/2026 A 10,362 (2) 05/11/2032 Common Stock 10,362 (3) 10,362 D Stock Option (right to buy) $ 17.28 03/19/2026 D 10,362 (2) 05/11/2032 Common Stock 10,362 (3) 0 D Stock Option (right to buy) $ 3.91 (1) 03/19/2026 A 23,742 (2) 06/06/2033 Common Stock 23,742 (3) 23,742 D Stock Option (right to buy) $ 5.91 03/19/2026 D 23,742 (2) 06/06/2033 Common Stock 23,742 (3) 0 D Explanation of Responses: 1. The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. 2. The option is fully vested. 3. On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. /s/ Lucy Day, Attorney-in-Fact for Gilbert Lynn Marks 03/23/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the

View Full Filing

View this 4 filing on SEC EDGAR